Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation

Int J Radiat Oncol Biol Phys. 1984 Jul;10(7):957-64. doi: 10.1016/0360-3016(84)90163-9.

Abstract

We examined 277 patients, who have been followed for 1 to 12 years after marrow transplantation, for cataract development. In preparation for transplantation, 96 patients with aplastic anemia were conditioned with chemotherapy only, usually cyclophosphamide 50 mg/kg X 4 intravenously, while 181 patients (two with aplastic anemia and 179 with a hematologic malignancy) were conditioned with a regimen of total body irradiation (TBI) and chemotherapy. TBI was delivered from two opposing 60Co sources at an exposure rate of 4 to 8 cGy/min, either as a single dose of 10 Gy (105 patients) or in fractions (76 patients), usually at increments of 2 to 2.25 Gy/day for 6 to 7 days for cumulative doses of 12 to 15.75 Gy. To date, 86 patients have developed cataracts. Kaplan-Meier product limit estimates of the incidence of cataracts for patients given chemotherapy only and no TBI, single-dose TBI, and fractionated TBI are 19, 80, and 18%, respectively. On the basis of proportional hazards regression analyses, patients given single-dose TBI had a relative risk of developing cataracts that was 4.7-fold higher than in patients given fractionated TBI or chemotherapy only (p less than 0.00005), suggesting a significant sparing effect with use of TBI dose fractionation. Addition significant risk factors included the chronic use of steroids posttransplant (highly associated with the presence of chronic graft-versus-host disease), and the diagnoses of acute lymphoblastic or chronic myelogenous leukemia.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Anemia, Aplastic / drug therapy
  • Anemia, Aplastic / radiotherapy
  • Anemia, Aplastic / therapy
  • Bone Marrow Transplantation*
  • Cataract / etiology*
  • Child
  • Child, Preschool
  • Cyclophosphamide / therapeutic use
  • Female
  • Humans
  • Infant
  • Leukemia / drug therapy
  • Leukemia / radiotherapy
  • Leukemia / therapy
  • Male
  • Middle Aged
  • Preoperative Care
  • Radiotherapy Dosage
  • Risk
  • Whole-Body Irradiation / adverse effects*

Substances

  • Cyclophosphamide